Genome patent overturned

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Science

By | August 1, 2008

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Sciences applied for the patent in the mid-1990s. But the ruling might really affect Eli Lilly, who has spent $50 million developing an antibody to neutrokine-alpha and is looking to spend another $250 million bringing the therapy through clinical trials, the Times reported.

Popular Now

  1. Optimism for Key Deer After Hurricane Irma
  2. Do Microbes Trigger Alzheimer’s Disease?
  3. Decoding the Tripping Brain
  4. Tattoo Ink Nanoparticles Persist in Lymph Nodes
    The Nutshell Tattoo Ink Nanoparticles Persist in Lymph Nodes

    Analysis of the bodies of deceased individuals can’t determine what effect these tattoo remnants have on lymph function, but researchers suggest dirty needles aren’t the only risk of the age-old practice.

AAAS